After grabbing 37740.0 shares, the institutional investor is now in possession of 37740.0 shares of the Healthcare Company. The new investment brought the stake of investor firm to 4.03% having worth around $0.24 million. Moreover, Commonwealth Equity Services LLC increased its share by 5039.0 to have a control over 5039.0 shares. And Geode Capital Management LLC raised its holdings to 7.0 shares by acquiring 2790.0 shares or 0.30% of the stake.
Cingulate Inc (CING) concluded trading on 12/27/23 at a closing price of $3.99, with 50.51 million shares of worth about $201.55 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -77.83% during that period and on Wednesday the price saw a gain of about 101.52%. Currently the company’s common shares owned by public are about 17.38M shares, out of which, 12.32M shares are available for trading.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
According to filings with the U.S. Securities and Exchange Commission (SEC), insiders took part in trade of the company’s stock for 4 times over the past 12 months. They bought 1,834,155 shares in 4 of the transactions. In 0 selling transactions, insiders dumped 0 shares.
The company recently came buying 0.0 shares which brought its stake up to 0.66% of the company’s outstanding shares.
Cingulate Inc (NASDAQ: CING) started trading at $3.79, above $1.81 from concluding price of the previous day. However, the stock later moved at a day high price of 5.1000, or with a gain of 101.52%. Stock saw a price change of 79.73% in past 5 days and over the past one month there was a price change of -41.67%. Year-to-date (YTD), CING shares are showing a performance of -80.05% which decreased to -79.12% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.90 but also hit the highest price of $38.60 during that period. The average intraday trading volume for Cingulate Inc shares is 15.90K. The stock is currently trading 7.81% above its 20-day simple moving average (SMA20), while that difference is down -35.91% for SMA50 and it goes to -71.72% lower than SMA200.
Armistice Capital LLC acquired 37740.0 shares of Cingulate Inc having value of about $0.24 million. Cingulate Inc (NASDAQ: CING) currently have 17.38M outstanding shares and institutions hold larger chunk of about 0.39% of that. Holding of mutual funds in the company is about 0.94% while other institutional holders and individual stake holders have control over 6.33% and — of the stake respectively.
The stock has a current market capitalization of $69.35M and its 3Y-monthly beta is at -1.06. It has posted earnings per share of -$32.59 in the same period. It has Quick Ratio of 0.51. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CING, volatility over the week remained 20.40% while standing at 20.88% over the month.
Analysts are in expectations that Cingulate Inc (CING) stock would likely to be making an EPS of -$4.86 in the current quarter, while forecast for next quarter EPS is -$3.78 and it is -$11.55 for next year. For the current quarter EPS, analysts have given the company a lowest target -$6.26 which is -$2.6 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$8.2 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 11.96% while it is estimated to increase by 57.95% in next year.
Analysts at 4 brokerage firms have issued recommendations for the Cingulate Inc (CING)’s stock and average of those rates the stock at a “Moderate Buy” and assign it a score of 2.00. Out of those 4 Wall Street analysts, 2 recommended a “Buy” rating, while 2 were in favor recommending the stock as a “Hold” and 0 analyst recommended the stock as “Sell”.
